These substitutions affect residues that (i) interact with eL6 (Leu-7, Val-35, Phe-43, Tyr-103, Asp-40-Tyr-44 and Pro-104-Ile-107) (Figs. S3 and S1-B), (ii) were found mutated in human DBA and in different tumor entities (Leu-29, Val-35 and Leu-7), or (iii) interact with different nucleotides of the 60S rRNA domain II (Leu-29) (Fig. S4-A), domain I and ES39 (from Lys-92 to Arg-99) (Fig. S4-B) and ES7 (Pro-104 and Asp106) (Fig. S1-C). Here, RPS19 is linked to neoplasm.